<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02854046</url>
  </required_header>
  <id_info>
    <org_study_id>RC16_0164</org_study_id>
    <nct_id>NCT02854046</nct_id>
  </id_info>
  <brief_title>Calciphylaxis : Population, Risk Factors, Diagnostic Practice, Therapeutic and Outcome</brief_title>
  <acronym>CalciWest</acronym>
  <official_title>Calciphylaxis : Population, Risk Factors, Diagnostic Practice, Therapeutic and Outcome : a Multicentric, Retrospective Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Calciphylaxis, also called Calcific Uremic Arteriolopathy (CUA) is a lethal affection mostly
      affecting patient in end stage renal disease. The survival rate is described around 20 to 46%
      at one year.

      Clinical presentation is very painful skin lesions with ulceration mostly located on the
      trunk or thigh.

      Current knowledge about physiopathology, diagnostic practice and therapeutic is very limited.

      Actually there is no European study about calciphylaxis and risk factors, diagnostic practice
      and outcome factors.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Description of calcific uremic arteriolopathy in a French population by describing the characteristics of the population, diagnostic and treatment practices and patient outcome.</measure>
    <time_frame>Up to 16 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Study factors determining the patient outcome with calciphylaxis</measure>
    <time_frame>Up to 16 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study case control of risk factors in the subgroup of patients in extra renal replacement therapy</measure>
    <time_frame>Up to 16 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Calciphylaxis</condition>
  <arm_group>
    <arm_group_label>Calciphylaxis Cases</arm_group_label>
    <description>Adult patients with advanced chronic kidney disease (DFG estimation &lt; 30 ml/min/1.73m² - beyond 3B stage) with/without substitute therapy who has presented a case of calciphylaxis (Calcific Uremic Arteriolopathy) between 2006 and 2016 in the Regions of Pays de la Loire, Centre Val de Loire, Bretagne and Poitou-Charentes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Witness cases</arm_group_label>
    <description>Selected anonymously in French national register REIN. Matched to Calciphylaxis Cases according to gender, age, treatment by extrarenal purification at the timepoint &quot;onset of the lesions&quot; and REIN regions belonging</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Calcific Uremic Arteriolopathy</intervention_name>
    <arm_group_label>Calciphylaxis Cases</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with advanced chronic kidney disease (DFG estimation &lt; 30 ml/min/1.73m² -
        beyond 3B stage) with/without subtitute therapy who has presented a case of calciphylaxis
        between 2006 and 2016 in the Régions of Pays de la Loire, Centre Val de Loire, Bretagne and
        Poitou-Charentes
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients ≥ 18 years with chronic renal failure with Glomerular Filtration Rate &lt;
             30ml/min/1,73m²

          -  diagnosis of calciphylaxis between 2006 and 2016

          -  living in the Regions of Bretagne, Pays de la Loire, Poitou-Charentes or Centre Val de
             Loire.

        Exclusion Criteria:

          -  realized biopsy in favor of differential diagnosis

          -  significant arterial lesion of lesion area or differential diagnosis more valid

          -  if the diagnosis is not based on the following criteria: 3 clinical criteria or 2
             clinical criteria and biopsy in favor, criteria which are :

               -  Patient in chronic hemodialysis or stade 4 chronic kidney disease

               -  At least 2 painful sores and hardly curable with concomitant painful purpura

               -  Sore and purpura localisation in trunk, extremities and penis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maryvonne HOURMANT, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David LARMET BURGEOT, MSc</last_name>
    <phone>+33 (0)632421652</phone>
    <email>larmet.david@orange.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maryvonne HOURMANT, PHD</last_name>
    <phone>+33(0)240087453</phone>
    <email>maryvonne.hourmant@chu-nantes.fr</email>
  </overall_contact_backup>
  <reference>
    <citation>Brandenburg VM, Kramann R, Rothe H, Kaesler N, Korbiel J, Specht P, Schmitz S, Krüger T, Floege J, Ketteler M. Calcific uraemic arteriolopathy (calciphylaxis): data from a large nationwide registry. Nephrol Dial Transplant. 2017 Jan 1;32(1):126-132. doi: 10.1093/ndt/gfv438.</citation>
    <PMID>26908770</PMID>
  </reference>
  <reference>
    <citation>Floege J, Kubo Y, Floege A, Chertow GM, Parfrey PS. The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial. Clin J Am Soc Nephrol. 2015 May 7;10(5):800-7. doi: 10.2215/CJN.10221014. Epub 2015 Apr 17.</citation>
    <PMID>25887067</PMID>
  </reference>
  <reference>
    <citation>Fine A, Zacharias J. Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int. 2002 Jun;61(6):2210-7.</citation>
    <PMID>12028462</PMID>
  </reference>
  <reference>
    <citation>Weenig RH, Sewell LD, Davis MD, McCarthy JT, Pittelkow MR. Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol. 2007 Apr;56(4):569-79. Epub 2006 Dec 1.</citation>
    <PMID>17141359</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2016</study_first_submitted>
  <study_first_submitted_qc>July 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2016</study_first_posted>
  <last_update_submitted>July 29, 2016</last_update_submitted>
  <last_update_submitted_qc>July 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>calcific uremic arteriolopathy</keyword>
  <keyword>case-control study</keyword>
  <keyword>cohort study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calciphylaxis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

